Literature DB >> 27781202

Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies.

Alessandro Cucchetti1, Alberta Cappelli2, Giorgio Ercolani1, Cristina Mosconi2, Matteo Cescon1, Rita Golfieri2, Antonio Daniele Pinna1.   

Abstract

BACKGROUND: Many patients with primary liver cancers are not candidates for surgery, and systemic therapies are seldom effective. Selective internal radiation therapy (SIRT) has been shown to obtain partial and even complete response in unresectable primary tumors. As a "side effect", SIRT can induce contra-lateral liver hypertrophy. Tumor response to SIRT can be sufficient to allow disengagement from normal vital structures whose involvement is the cause of the initial unresectability. The contra-lateral hypertrophy can thereby increase the future liver remnant (FLR) volume to over the safe threshold so that extended hepatectomy can be performed.
SUMMARY: A review of the available literature was performed to assess the tumor response and liver hypertrophy that can be expected after SIRT, in order to delineate whether SIRTcan play a role in conversion therapy for resectability of primary liver malignancies. KEY MESSAGE: Available data suggest that SIRT in unresectable hepatocellular and cholangiocellular carcinomas can provide a considerable down-sizing of the tumors to possibly allow resection. Hypertrophy of the contra-lateral lobe represents a favorable collateral effect that can help in achieving safer subsequent major hepatectomy. In patients whose FLR volume represents the only surgical concern, portal vein embolization remains the treatment of choice.

Entities:  

Keywords:  Cholangiocellular carcinoma; Hepatocellular carcinoma; Radioembolization; Surgery; Yttrium-90

Year:  2016        PMID: 27781202      PMCID: PMC5075901          DOI: 10.1159/000449341

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  44 in total

Review 1.  Small for size liver remnant following resection: prevention and management.

Authors:  Rony Eshkenazy; Yael Dreznik; Eylon Lahat; Barak Bar Zakai; Alex Zendel; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

Authors:  Philip Hilgard; Monia Hamami; Amr El Fouly; André Scherag; Stefan Müller; Judith Ertle; Till Heusner; Vito R Cicinnati; Andreas Paul; Andreas Bockisch; Guido Gerken; Gerald Antoch
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

3.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

Review 5.  Yttrium-90 microspheres: a review of its emerging clinical indications.

Authors:  Natthida Khajornjiraphan; Nyein Aye Thu; Pierce Kah Hoe Chow
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

6.  Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.

Authors:  Juan C Camacho; Nima Kokabi; Minzhi Xing; Hasmukh J Prajapati; Bassel El-Rayes; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2014-02       Impact factor: 3.464

7.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.

Authors:  Samdeep Mouli; Khairuddin Memon; Talia Baker; Al B Benson; Mary F Mulcahy; Ramona Gupta; Robert K Ryu; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2013-04-19       Impact factor: 3.464

9.  Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

Authors:  Brian I Carr; Venkateswarlu Kondragunta; Shama C Buch; Robert A Branch
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

Review 10.  Hepatic radioembolization as a bridge to liver surgery.

Authors:  Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Front Oncol       Date:  2014-07-30       Impact factor: 6.244

View more
  7 in total

Review 1.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

Review 2.  Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.

Authors:  D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser
Journal:  J Gastrointest Oncol       Date:  2020-04

3.  Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma.

Authors:  Michael Vouche; Thierry Degrez; Fikri Bouazza; Philippe Delatte; Maria Gomez Galdon; Alain Hendlisz; Patrick Flamen; Vincent Donckier
Journal:  World J Hepatol       Date:  2017-12-28

4.  Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes.

Authors:  Sebastian Mafeld; Peter Littler; Hannah Hayhurst; Derek Manas; Ralph Jackson; John Moir; Jeremy French
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 5.  Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Authors:  Rui Xing; Jinping Gao; Qi Cui; Qian Wang
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

Review 6.  SIRT in 2025.

Authors:  Francesca Romana Ponziani; Francesco Santopaolo; Antonio Gasbarrini; Roberto Iezzi; Alessandro Posa; Maurizio Pompili; Alessandro Tanzilli; Marta Maestri; Maria Pallozzi; Francesca Ibba; Riccardo Manfredi
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-08       Impact factor: 2.797

7.  Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.

Authors:  Erman Aytaç; Leyla Özer; Bilgi Baca; Emre Balık; Yersu Kapran; Orhun Cığ Taşkın; Başak Oyan Uluç; Mehmet Ufuk Abacıoğlu; Murat Gönenç; Yasemin Bölükbaşı; Barbaros E Çil; Bülent Baran; Cem Aygün; Mehmet Erdem Yıldız; Kemal Ünal; Burçak Erkol; Tunç Yaltı; Uğur Özbek; Tan Attila; Nurdan Tözün; Bengi Gürses; Sibel Erdamar; Özlem Er; Nuran Beşe; Orhan Bilge; Güralp Onur Ceyhan; Nil Molinas Mandel; Uğur Selek; Cengiz Yakıcıer; Hülya Kayserili Karabey; Murat Saruç; Volkan Özben; Eren Esen; Emre Özoran; Erkan Vardareli; Levent Güner; İsmail Hamzaoğlu; Dursun Buğra; Tayfun Karahasanoğlu; The İstanbul Group
Journal:  Turk J Gastroenterol       Date:  2022-08       Impact factor: 1.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.